<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521378</url>
  </required_header>
  <id_info>
    <org_study_id>DP 01-2007-01</org_study_id>
    <nct_id>NCT00521378</nct_id>
  </id_info>
  <brief_title>A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diasome Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diasome Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study designed to determine the appropriate doses of Oral HDV Insulin at meal times.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must satisfy all of the following inclusion criteria to be included in the study:

          1. be male or female between the ages of18 and 65 years, inclusive;

          2. have a current diagnosis of type 2 DM, which is currently managed with oral
             hypoglycemic agents for at least 3 months;

          3. have a current physical examination that reveals no clinically significant
             abnormalities;

          4. have no clinically significant abnormalities in vital signs;

          5. have a body mass index (BMI) &lt;38;

          6. have a glycosylated hemoglobin (HbA1c) &gt; 8 and &lt;12;

          7. have a C-peptide level &gt;3 ng/mL;

          8. have a typical fasting blood glucose levels of &lt; 200 mg/dl (+/- 25 mg/dl);

          9. be available for the entire study period, and be able and willing to adhere to
             protocol requirements;

         10. if female of childbearing potential, must be using a reliable form of birth control;
             and,

         11. provide written informed consent prior to admission into the study.

        Exclusion Criteria:

          1. have a history or presence of significant cardiac, gastrointestinal, endocrine,
             neurological, liver, or kidney disease, or conditions known to interfere with the
             absorption, distribution, metabolism, or excretion of insulin;

          2. have a history of drug or alcohol dependency or psychological disease;

          3. have any clinically significant illness during the 4 weeks prior to admission into the
             study;

          4. require regular use of medication that interferes with the absorption and/or
             metabolism of insulin;

          5. recent use (within 48 hours) of medications that interfere with blood glucose
             analyses, i.e., mannose, acetaminophen, dopamine, and ascorbic acid, which are all
             reported to alter glucose-oxidase type blood glucose analytical methods;

          6. use of Avandia or Actos for treating diabetes;

          7. participation in a clinical trial or use of an investigational drug within 30 days
             prior to admission to this study;

          8. use of MAO inhibitors or enzyme-inducing or enzyme-inhibiting agents (eg,
             phenobarbital or carbamazepine) within 30 days prior to admission to this study;

          9. are pregnant or lactating; 10. have an episode of severe hypoglycemia with seizure or
             coma within the past year;

        11. have a history of ketoacidosis;

        12. have any acute illness within 2 weeks prior to Screening; or,

        13. have elevated liver enzymes (ALT, AST, alkaline phosphatase) &gt;1.5 times the upper limit
        of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <last_update_submitted>January 10, 2009</last_update_submitted>
  <last_update_submitted_qc>January 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <keyword>Diabetes</keyword>
  <keyword>Type 1 and Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

